Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06066905 | A Study of Chidamide With AZA in MRD Positive AML After Transplant | recruiting | N/A | 60 | Guangdong Provincial People's HospitalOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT03825796 | CPX-351 Plus Enasidenib for Relapsed AML | active not recruiting | Phase 2 | 2 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06022341 |
| MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies(MOZART) |
| not yet recruiting |
| N/A |
| 120 |
| University Hospital, AngersOTHER_GOV |
| 0 |
| Sep 1, 2023 |
| clinicaltrials |
| NCT00003861 | Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia | active not recruiting | — | 840 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 31, 2023 | clinicaltrials |
| NCT05979675 | Acute Myeloid Leukemia Registry(AMLREGISTRY) | recruiting | — | 250 | Turkish Hematology AssociationOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT04645706 | Innate T Cells and TKI Discontinuation(TIBIOP-LMC) | active not recruiting | — | 92 | Poitiers University HospitalOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02665065 | Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia(SIERRA) | active not recruiting | Phase 3 | 153 | Actinium PharmaceuticalsINDUSTRY | 2 | Jul 19, 2023 | clinicaltrials |
| NCT05875649 | A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure(CLAG) | not yet recruiting | — | 137 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05909293 | Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission | recruiting | N/A | 100 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05882773 | Asian Myeloproliferative Neoplasm (MPN) Registry | recruiting | — | 1,000 | The University of Hong KongOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05876832 | A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) | not yet recruiting | Phase 3 | 312 | Shijiazhuang Yiling Pharmaceutical Co. LtdINDUSTRY | 0 | May 26, 2023 | clinicaltrials |
| NCT05805098 | Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML(VHA) | recruiting | Phase 2 / Phase 3 | 60 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05736965 | A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia(SAV) | recruiting | Phase 2 | 58 | Shanghai Tong Ren HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05736978 | Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results(AVS) | recruiting | Phase 2 | 58 | Shanghai Tong Ren HospitalOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT05367700 | A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. | recruiting | Phase 1 | 108 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 13, 2023 | clinicaltrials |
| NCT05584761 | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT03852407 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning(HLA) | recruiting | Phase 2 | 114 | University of LiegeOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05521204 | Olverembatinib for FGFR1-rearranged Neoplasms | recruiting | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 30, 2022 | clinicaltrials |
| NCT03645824 | Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF)(HOVON134MF) | active not recruiting | Phase 2 | 61 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 2 | Aug 22, 2022 | clinicaltrials |
| NCT05404906 | AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission | recruiting | Phase 2 / Phase 3 | 124 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05506332 | Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 10 | University Hospital, AntwerpOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT01744223 | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 36 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05445011 | Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 12 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05445154 | SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 58 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05440747 | Treatment Free Remission (TFR) in CML Patients （CML-CP）Study | not yet recruiting | — | 203 | Guangdong Provincial People's HospitalOTHER | 0 | Jul 1, 2022 | clinicaltrials |
| NCT05431257 | Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling(LD-VenEx) | recruiting | Phase 2 | 117 | Rigshospitalet, DenmarkOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT05367765 | A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | not yet recruiting | Phase 4 | 2,400 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 10, 2022 | clinicaltrials |
| NCT05161026 | Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry(REMODALLO) | not yet recruiting | N/A | 120 | University Hospital, CaenOTHER | 1 | Dec 16, 2021 | clinicaltrials |
| NCT04769947 | Italian Treatment Free Remission Registry | recruiting | — | 800 | University of Turin, ItalyOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT04662294 | CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases | recruiting | Early Phase 1 | 108 | Zhejiang UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT05055791 | A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 312 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Sep 24, 2021 | clinicaltrials |
| NCT05025098 | Precision Therapy Versus Standard Therapy in AML and MDS in Elderly(PALM) | recruiting | Phase 2 | 36 | University Hospital, AkershusOTHER | 1 | Aug 27, 2021 | clinicaltrials |
| NCT04658004 | NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT04451200 | Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning(BUSEQ) | not yet recruiting | Phase 2 | 82 | Institut Paoli-CalmettesOTHER | 0 | Nov 17, 2020 | clinicaltrials |
| NCT04599543 | IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | Oct 27, 2020 | clinicaltrials |
| NCT03669965 | KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera | active not recruiting | Phase 2 | 20 | Kartos Therapeutics, Inc.INDUSTRY | 6 | Jul 31, 2020 | clinicaltrials |
| NCT03284593 | Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition(LAM-BDD) | active not recruiting | — | 199 | University Hospital, ToulouseOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT04167696 | Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02(CYCLE-1) | recruiting | Phase 1 | 27 | Celyad Oncology SAINDUSTRY | 2 | Jun 9, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Oct 27, 2023source: clinicaltrials